Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (281-290 of 388) with videos related to

Pageof 39
Sort By:
Journal of Hepatology|June 26, 2012
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trialJordi Bruix, Jean-Luc Raoul, Morris Sherman, et al.
Virchows Archiv : an International Journal of Pathology|November 8, 2023
mTOR eosinophilic renal cell carcinoma: a distinctive tumor characterized by mTOR mutation, loss of chromosome 1, cathepsin-K expression, and response to target therapyAnna Caliò, Stefano Marletta, Giulio Settanni, et al.
European Urology Oncology|January 31, 2023
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR StudyViktor Grünwald, Thomas Powles, Evgeny Kopyltsov, et al.
Breast (Edinburgh, Scotland)|October 25, 2022
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclibMarzia Del Re, Stefania Crucitta, Claudia Omarini, et al.
American Journal of Cancer Research|December 19, 2014
Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitorsClaudia Fiorini, Francesco Massari, Serena Pedron, et al.
Oncotarget|January 26, 2017
Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinomaNicola Personeni, Laura Giordano, Giovanni Abbadessa, et al.
World Journal of Clinical Oncology|December 15, 2021
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case seriesSebastiano Buti, Melissa Bersanelli, Francesco Massari, et al.
Clinical Genitourinary Cancer|July 19, 2024
Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal CancerMarzia Del Re, Stefania Crucitta, Nicole Brighi, et al.
BJU International|June 30, 2018
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programmeUgo De Giorgi, Giacomo Cartenì, Diana Giannarelli, et al.
European Urology|July 14, 2020
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical TrialBrian I Rini, Robert J Motzer, Thomas Powles, et al.
Pageof 39

Showing results (281-290 of 388) with videos related to

Sort By:
Pageof 39
Journal of Hepatology|June 26, 2012
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trialJordi Bruix, Jean-Luc Raoul, Morris Sherman, et al.
Virchows Archiv : an International Journal of Pathology|November 8, 2023
mTOR eosinophilic renal cell carcinoma: a distinctive tumor characterized by mTOR mutation, loss of chromosome 1, cathepsin-K expression, and response to target therapyAnna Caliò, Stefano Marletta, Giulio Settanni, et al.
European Urology Oncology|January 31, 2023
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR StudyViktor Grünwald, Thomas Powles, Evgeny Kopyltsov, et al.
Breast (Edinburgh, Scotland)|October 25, 2022
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclibMarzia Del Re, Stefania Crucitta, Claudia Omarini, et al.
American Journal of Cancer Research|December 19, 2014
Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitorsClaudia Fiorini, Francesco Massari, Serena Pedron, et al.
Oncotarget|January 26, 2017
Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinomaNicola Personeni, Laura Giordano, Giovanni Abbadessa, et al.
World Journal of Clinical Oncology|December 15, 2021
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case seriesSebastiano Buti, Melissa Bersanelli, Francesco Massari, et al.
Clinical Genitourinary Cancer|July 19, 2024
Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal CancerMarzia Del Re, Stefania Crucitta, Nicole Brighi, et al.
BJU International|June 30, 2018
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programmeUgo De Giorgi, Giacomo Cartenì, Diana Giannarelli, et al.
European Urology|July 14, 2020
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical TrialBrian I Rini, Robert J Motzer, Thomas Powles, et al.
Pageof 39